Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

A Multi-Center Study of BRCA1 and BRCA2 Germline Mutations in Mexican-Mestizo Breast Cancer Families Reveals Mutations Unreported in Latin American Population.

Millan Catalan O, Campos-Parra AD, Vázquez-Romo R, Cantú de León D, Jacobo-Herrera N, Morales-González F, López-Camarillo C, Rodríguez-Dorantes M, López-Urrutia E, Pérez-Plasencia C.

Cancers (Basel). 2019 Aug 26;11(9). pii: E1246. doi: 10.3390/cancers11091246.

2.

Crosstalk Between Long Non-coding RNAs, Micro-RNAs and mRNAs: Deciphering Molecular Mechanisms of Master Regulators in Cancer.

López-Urrutia E, Bustamante Montes LP, Ladrón de Guevara Cervantes D, Pérez-Plasencia C, Campos-Parra AD.

Front Oncol. 2019 Jul 25;9:669. doi: 10.3389/fonc.2019.00669. eCollection 2019. Review.

3.

miRNA profile obtained by next‑generation sequencing in metastatic breast cancer patients is able to predict the response to systemic treatments.

Martinez-Gutierrez AD, Catalan OM, Vázquez-Romo R, Porras Reyes FI, Alvarado-Miranda A, Lara Medina F, Bargallo-Rocha JE, Orozco Moreno LT, Cantú De León D, Herrera LA, López-Camarillo C, Pérez-Plasencia C, Campos-Parra AD.

Int J Mol Med. 2019 Oct;44(4):1267-1280. doi: 10.3892/ijmm.2019.4292. Epub 2019 Jul 30.

4.

HypoxamiRs Profiling Identify miR-745 as a Regulator of the Early Stages of Vasculogenic Mimicry in SKOV3 Ovarian Cancer Cells.

Salinas-Vera YM, Gallardo-Rincón D, García-Vázquez R, Hernández-de la Cruz ON, Marchat LA, González-Barrios JA, Ruíz-García E, Vázquez-Calzada C, Contreras-Sanzón E, Resendiz-Hernández M, Astudillo-de la Vega H, Cruz-Colin JL, Campos-Parra AD, López-Camarillo C.

Front Oncol. 2019 May 14;9:381. doi: 10.3389/fonc.2019.00381. eCollection 2019.

5.

Cell migration and proliferation are regulated by miR-26a in colorectal cancer via the PTEN-AKT axis.

Coronel-Hernández J, López-Urrutia E, Contreras-Romero C, Delgado-Waldo I, Figueroa-González G, Campos-Parra AD, Salgado-García R, Martínez-Gutierrez A, Rodríguez-Morales M, Jacobo-Herrera N, Terrazas LI, Silva-Carmona A, López-Camarillo C, Pérez-Plasencia C.

Cancer Cell Int. 2019 Apr 2;19:80. doi: 10.1186/s12935-019-0802-5. eCollection 2019.

6.

BRCA mutations: is everything said?

López-Urrutia E, Salazar-Rojas V, Brito-Elías L, Coca-González M, Silva-García J, Sánchez-Marín D, Campos-Parra AD, Pérez-Plasencia C.

Breast Cancer Res Treat. 2019 Jan;173(1):49-54. doi: 10.1007/s10549-018-4986-5. Epub 2018 Oct 6. Review.

PMID:
30293211
7.

Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer.

Campos-Parra AD, López-Urrutia E, Orozco Moreno LT, López-Camarillo C, Meza-Menchaca T, Figueroa González G, Bustamante Montes LP, Pérez-Plasencia C.

Int J Mol Sci. 2018 Sep 11;19(9). pii: E2711. doi: 10.3390/ijms19092711. Review.

8.

MicroRNA-125 modulates radioresistance through targeting p21 in cervical cancer.

Pedroza-Torres A, Campos-Parra AD, Millan-Catalan O, Loissell-Baltazar YA, Zamudio-Meza H, Cantú de León D, Montalvo-Esquivel G, Isla-Ortiz D, Herrera LA, Ángeles-Zaragoza Ó, Robelo-Romero G, Herrera-Gómez Á, Pérez-Plasencia C.

Oncol Rep. 2018 Mar;39(3):1532-1540. doi: 10.3892/or.2018.6219. Epub 2018 Jan 18.

PMID:
29399698
9.

A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer.

García-Vazquez R, Ruiz-García E, Meneses García A, Astudillo-de la Vega H, Lara-Medina F, Alvarado-Miranda A, Maldonado-Martínez H, González-Barrios JA, Campos-Parra AD, Rodríguez Cuevas S, Marchat LA, López-Camarillo C.

Tumour Biol. 2017 Jun;39(6):1010428317702899. doi: 10.1177/1010428317702899.

PMID:
28621239
10.

Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications.

Campos-Parra AD, Mitznahuatl GC, Pedroza-Torres A, Romo RV, Reyes FIP, López-Urrutia E, Pérez-Plasencia C.

Int J Mol Sci. 2017 Jun 2;18(6). pii: E1182. doi: 10.3390/ijms18061182. Review.

11.

MicroRNAs are involved in cervical cancer development, progression, clinical outcome and improvement treatment response (Review).

González-Quintana V, Palma-Berré L, Campos-Parra AD, López-Urrutia E, Peralta-Zaragoza O, Vazquez-Romo R, Pérez-Plasencia C.

Oncol Rep. 2016 Jan;35(1):3-12. doi: 10.3892/or.2015.4369. Epub 2015 Oct 30. Review.

PMID:
26530778
12.

Relevance of the novel IASLC/ATS/ERS classification of lung adenocarcinoma in advanced disease.

Campos-Parra AD, Avilés A, Contreras-Reyes S, Rojas-Marín CE, Sánchez-Reyes R, Borbolla-Escoboza RJ, Arrieta O.

Eur Respir J. 2014 May;43(5):1439-47. doi: 10.1183/09031936.00138813. Epub 2014 Jan 16.

13.

KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making.

Campos-Parra AD, Zuloaga C, Manríquez ME, Avilés A, Borbolla-Escoboza J, Cardona A, Meneses A, Arrieta O.

Am J Clin Oncol. 2015 Feb;38(1):33-40. doi: 10.1097/COC.0b013e318287bb23.

PMID:
23538866
14.

Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure.

Arrieta O, Campos-Parra AD, Zuloaga C, Avilés A, Sánchez-Reyes R, Manríquez ME, Covián-Molina E, Martínez-Barrera L, Meneses A, Cardona A, Borbolla-Escoboza JR.

J Thorac Oncol. 2012 Aug;7(8):1228-34. doi: 10.1097/JTO.0b013e3182582a93.

15.

Genotyping non-small cell lung cancer (NSCLC) in Latin America.

Arrieta O, Cardona AF, Federico Bramuglia G, Gallo A, Campos-Parra AD, Serrano S, Castro M, Avilés A, Amorin E, Kirchuk R, Cuello M, Borbolla J, Riemersma O, Becerra H, Rosell R; CLICaP.

J Thorac Oncol. 2011 Nov;6(11):1955-9. doi: 10.1097/JTO.0b013e31822f655f.

Supplemental Content

Loading ...
Support Center